Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine Studie zu Gemcitabin/Cisplatin plus Cemiplimab (REGN2810, Anti-PD-1) mit oder ohne Fianlimab (REGN3767, Anti-LAG-3) bei Patienten mit lokalisiertem muskelinvasivem Blasenkrebs (NeoSTOP-IT) (NeoSTOP-IT)

12. Oktober 2026 aktualisiert von: Alexander Z. Wei, MD, Columbia University

Eine randomisierte, offene Phase-2-Studie mit Gemcitabin/Cisplatin plus Cemiplimab (REGN2810, Anti-PD-1) mit oder ohne Fianlimab (REGN3767, Anti-LAG-3) zur Organerhaltung bei Patienten mit lokalisiertem muskelinvasivem Blasenkrebs (NeoSTOP-IT)

The goal of this clinical trial is to learn if gemcitabine/cisplatin plus cemiplimab with or without fianlimab works to treat bladder cancer in adults. The main question it aims to answer is: Can gemcitabine, cisplatin, and cemiplimab with or without fianlimab treat bladder cancer?

Participants will be randomly selected (like the loss of a coin) to treatment with gemcitabine, cisplatin, cemiplimab, and fianlimab or gemcitabine, cisplatin, and cemiplimab.

Participants will:

  • Undergo transurethral resection of bladder tumor (TURBT) followed by the start of treatment, receive 4 cycles of treatment (21 day cycles)
  • After 4 cycles of treatment, patients will undergo repeat maximal TURBT with imaging
  • Participants with a complete response will continue maintenance cemiplimab or cemiplimab/fianlimab for 13 more cycles with imaging every 3 months
  • Participants without a complete clinical response will undergo cystectomy (bladder surgery).

Studienübersicht

Detaillierte Beschreibung

This is a phase 2, open-label, randomized trial with continuous toxicity monitoring to ensure safety using Bayesian toxicity monitoring, which will evaluate treatment with doublet platinum-based chemotherapy (gemcitabine and cisplatin) plus cemiplimab (REGN2810) with or without fianlimab (REGN3767) for localized muscle-invasive bladder cancer (MIBC). Participants will be randomized to 4 cycles of 3 weeks each (12 weeks total) with gemcitabine, cisplatin, and cemiplimab with or without fianlimab. Participants achieving a clinical complete response will continue 13 more cycles of immunotherapy (39 weeks total). The total duration of systemic treatment, including neoadjuvant therapy, will be 52 weeks.

In addition to the actual time on treatment, there will be time off treatment for recovery after neoadjuvant treatment and before adjuvant treatment. First, between the neoadjuvant phase and cystoscopy (with TURBT for residual disease), there will be up to 4 weeks off treatment. In between the cystoscopy/TURBT and start of adjuvant immunotherapy, there will be an additional up to 4 week interval for recovery. Participants will have regularly scheduled study visits at the clinical site on Day 1 and Day 8 of every three-week cycle in the neoadjuvant setting, where continuous assessment, including treatment response and safety assessments, will be performed. These will include laboratory tests, taking of vital signs, and physical examinations. In the adjuvant setting for participants who continue to maintenance immunotherapy, participants will have regularly scheduled study visits at the clinical site on Day 1 of every three-week cycle.

Response to treatment will be determined by three modalities. First, CT scans (chest, abdomen, and pelvis with and without contrast) to ensure no metastatic disease. For participants who are unable to get a CT scan w/ contrast due to renal function (or any other reason), an MRI with and without contrast may be used instead. Scans are required at baseline and every 3 months in the adjuvant setting for participants who continue on with maintenance immunotherapy. Second, all participants will undergo post-treatment cystoscopy every 3 months while on treatment. Third, all participants will undergo post-treatment urine cytology every 3 months while on treatment.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

1

Phase

  • Phase 2

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • New York
      • New York, New York, Vereinigte Staaten, 10032
        • Columbia University Irving Medical Center/ New York Presbyterian Hospital

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Willing and able to provide written informed consent for the trial.
  • Age ≥18 years of age on day of signing informed consent.
  • Life expectancy > 12 months.
  • Performance status of 0-1 using the Eastern Cooperative Oncology Group (ECOG) Performance Scale.
  • Histologically confirmed muscle-invasive urothelial carcinoma of the bladder defined as T2-T3, N0, M0 stage. Mixed histology is permitted if there is a urothelial component. Upper tract disease in not permitted.
  • Prior Bacillus Calmette-Guerin (BCG) or other intravesical treatment of non-muscle invasive bladder cancer is permitted if completed at least 6 weeks prior to initiating study treatment. Only one course (includes induction + maintenance) of BCG or intravesical therapy is permitted.
  • No metastatic disease based on cross-sectional imaging.
  • Considered cisplatin eligible based on protocol specified criteria.
  • Not received any adjuvant or neoadjuvant chemotherapy or immunotherapy.
  • Agree to pre- and post-treatment TURBT as well as surveillance with cystoscopies, cross-sectional imaging, and urine cytology unless medically contraindicated in the opinion of the treating physician, and discussed with the principal investigator

Exclusion Criteria:

  • Concurrent upper urinary tract (i.e., ureter, renal pelvis) invasive urothelial carcinoma. (NOTE: Patients with history of non-invasive (Ta, Tis) upper tract urothelial carcinoma that has been definitively treated with at least one post- treatment disease assessment (i.e. cytology, biopsy, imaging) that demonstrates no evidence of residual disease are eligible).
  • Received prior immune checkpoint inhibitors (including anti-PD-1, anti-PD-L1, anti-CTLA4, anti-LAG-3 or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways ), as well as cellular vaccines, cellular therapies, or systemic oncolytic virus therapy.
  • Received bladder-directed radiation therapy previously for bladder cancer.
  • Received prior systemic chemotherapy for muscle-invasive bladder cancer.
  • Receiving any other investigational agents concurrently or within 4 weeks of start of treatment.
  • Had a solid organ or hematologic transplant.
  • Ongoing or recent (within 2 years) evidence of an autoimmune disease that required systemic treatment with immunosuppressive agents. The following are non-exclusionary: vitiligo, childhood asthma that has resolved, residual hypothyroidism that requires only hormone replacement, psoriasis not requiring systemic treatment
  • Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (at a dose greater than 10mg/day of prednisone equivalent) or any other form of immunosuppressive therapy within 14 days prior to the first dose of trial treatment. Inhaled or topical steroids, and adrenal replacement steroid doses >10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
  • Has a history of myocarditis.
  • Patients with another active second malignancy other than non-melanoma skin cancers.
  • Has a known history of, or any evidence of, interstitial lung disease or active noninfectious pneumonitis.
  • Has an active infection requiring systemic therapy.
  • History or current evidence of significant (Common Terminology Criteria for Adverse Events (CTCAE) grade ≥2) local or systemic infection (eg, cellulitis, pneumonia, septicemia) requiring systemic antibiotic treatment within 2 weeks prior to the first dose of trial medication.
  • Has a history of current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator, including dialysis.
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  • Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection; or diagnosis of immunodeficiency that is related to, or results in chronic infection.
  • Is pregnant or is a breastfeeding woman.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Group 1: Gemcitabine/Cisplatin/Cemiplimab
  • Gemcitabine 1000 mg/m^2 IV (days 1 and 8 of 21 day for 4 cycles)
  • Cisplatin 70 mg/m^2 IV (day 1 of 21 day cycle for 4 cycles) or renally-dosed split-dose -cisplatin 35 m/m^2 IV (day 1 and 8 of 21 day cycle for 4 cycles)
  • Cemiplimab (REGN 2810) 350 mg IV every 3 weeks (17 cycles)

Gemcitabine 1000 mg/m^2 IV

Cisplatin 70 mg/m^2 IV or renally-dosed split-dose cisplatin 35 m/m^2 IV

Cemiplimab 350mg IV

Andere Namen:
  • REGN 2810
Experimental: Group 2: Gemcitabine/Cisplatin/Cemiplimab/Fianlimab
  • Gemcitabine 1000 mg/m2 IV (days 1 and 8 of 21 day cycle for 4 cycles)
  • Cisplatin 70 mg/m2 IV (day 1 of 21 day cycle for 4 cycles) or renally-dosed split-dose cisplatin 35 m/m2 IV (day 1 and 8 of 21 day cycle for 4 cycles )
  • Cemiplimab (REGN 2810) 350mg IV every 3 weeks (4 cycles)
  • Fianlimab (REGN3767) 1600mg IV every 3 weeks (4 cycles)

Gemcitabine 1000 mg/m^2 IV

Cisplatin 70 mg/m^2 IV or renally-dosed split-dose cisplatin 35 m/m^2 IV

Cemiplimab 350mg IV

Andere Namen:
  • REGN 2810

Fianlimab 1600mg IV

Andere Namen:
  • REGN3767

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Clinical Complete Response
Zeitfenster: 16 weeks

Rate of clinical complete response after 4 cycles of neoadjuvant chemoimmunotherapy. Complete clinical response will be defined as:

  • No high-grade malignancy on repeat TURBT
  • No malignant cells on urine cytology
  • No definitive evidence of invasive local or metastatic disease on cross-sectional imaging (CT chest, abdomen, and pelvis with contrast or, if renal dysfunction, MRI with contrast)

Cytoscopy and imaging should occur within 4 weeks of end of neoadjuvant therapy.

16 weeks

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Number of Adverse Events
Zeitfenster: 30 days after last dose of treatment, up to 56 weeks

Defined as the occurrence of any adverse event (AE) related to the investigational drugs at any point on treatment until 30 days after the last dose of treatment. AEs as evaluated per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

30 days after last dose of treatment, up to 56 weeks
Bladder-intact Survival
Zeitfenster: Up to 5 years

Bladder-intact survival is defined as the time from start of treatment until cystectomy or death.

Up to 5 years
Recurrence-free Survival
Zeitfenster: Up to 5 years

Recurrence-free survival is defined as the time from start of treatment until disease recurrence or death. Recurrence-survival will only be measured in patients who achieve a clinical complete response.

Up to 5 years
Overall Survival
Zeitfenster: Up to 5 years

Overall survival is defined as the time from start of treatment until death.

Up to 5 years

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Alexander Z Wei, MD, Columbia University

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

14. August 2025

Primärer Abschluss (Tatsächlich)

5. Januar 2026

Studienabschluss (Tatsächlich)

5. Januar 2026

Studienanmeldedaten

Zuerst eingereicht

23. August 2024

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

23. August 2024

Zuerst gepostet (Tatsächlich)

26. August 2024

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

3. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

12. Oktober 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Ja

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren